Notch3 targeting. A novel weapon against ovarian cancer stem cells by Ceccarelli, Simona et al.
Review Article
Notch3 Targeting: A Novel Weapon against Ovarian Cancer
Stem Cells
Simona Ceccarelli ,1 Francesca Megiorni ,1,2 Diana Bellavia ,3 Cinzia Marchese ,1
Isabella Screpanti ,3 and Saula Checquolo 4
1Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy
2Department of Pediatrics, “Sapienza” University of Rome, Italy
3Department of Molecular Medicine, “Sapienza” University of Rome, Rome, Italy
4Department of Medico-Surgical Sciences and Biotechnology, Sapienza University, Latina, Italy
Correspondence should be addressed to Isabella Screpanti; isabella.screpanti@uniroma1.it
and Saula Checquolo; saula.checquolo@uniroma1.it
Received 26 October 2018; Accepted 9 December 2018; Published 6 January 2019
Academic Editor: Sieghart Sopper
Copyright © 2019 Simona Ceccarelli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Notch signaling is frequently activated in ovarian cancer (OC) and contributes to the proliferation and survival of cultured OC cells
as well as to tumor formation and angiogenesis in xenograft models. Several studies demonstrate that Notch3 expression renders
cancer cells more resistant to carboplatin, contributing to chemoresistance and poor survival of OC-bearing patients. This suggests
that Notch3 can represent both a biomarker and a target for therapeutic interventions in OC patients. Although it is still unclear
how chemoresistance arises, different lines of evidence support a critical role of cancer stem cells (CSCs), suggesting that CSC
targeting by innovative therapeutic approaches might represent a promising tool to efficiently reduce OC recurrence. To date,
CSC-directed therapies in OC tumors are mainly targeted to the inhibition of CSC-related signaling pathways, including Notch.
As it is increasingly evident the involvement of Notch signaling, and in particular of Notch3, in regulating stem-like cell
maintenance and expansion in several tumors, here we provide an overview of the current knowledge of Notch3 role in
CSC-mediated OC chemoresistance, finally exploring the potential design of innovative Notch3 inhibition-based therapies for
OC treatment, aimed at eradicating tumor through the suppression of CSCs.
1. Introduction
Ovarian cancer (OC) is relatively rare (nearly 3% of all female
tumors) but it represents the most lethal gynecologic malig-
nancy worldwide, being the fifth principal cause of cancer
mortality in women [1]. About 200,000 new OC cases are
estimated worldwide every year, with 150,000 deaths [2].
This high mortality-to-incidence ratio is essentially due to
the absence of OC-specific symptoms and the lack of effective
screening strategies that lead many women to be diagnosed at
an advanced stage of the disease, when cancer metastases are
already present in the abdominal cavity [3]. Currently,
despite the standard therapies, including cytoreduction and
platinum/paclitaxel administration, which may lead to
clinical remission, about 70% of patients relapse developing
a resistance to first-line drugs [4]. Indeed, the general prog-
nosis in OC patients remains poor, with a 5-year survival rate
of about 50% [1].
In this scenario, the high percentage of therapeutic failure
is mainly due to the occurrence of drug resistance, which is
directly correlated with the presence of cancer stem cells
(CSCs) [5–7]. Molecular profiling of ovarian CSCs has been
performed to identify both stemness-related surface markers
and molecular pathways important for CSC function [6].
Besides the high number of genes related to drug efflux and
DNA damage repair, which contribute to CSC resistance to
conventional chemotherapy, the specific role of Notch sig-
naling pathway, mainly of Notch3, has been well established
in the regulation of CSC behavior and platinum chemoresis-
tance [6]. Notch signaling is a conserved pathway commonly
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implicated in the maintenance of tissue homeostasis by
regulating self-renewal of stem cells and differentiation of
progenitor cells in several organs and tissues [8–10]. More
recently, it has been demonstrated a novel specific role of
Notch3 in neural stem cell maintenance in the adult brain,
through a dual control of both stemness and quiescence [11].
In keeping with this, Notch signaling dysregulation is
correlated with the acquisition and maintenance of
CSC-like properties in several tumors [12, 13], including
brain [14], lung [15], breast [16], liver [17] and ovarian
cancers [6], thus suggesting its emerging role as an attractive
therapeutic target, as Notch inhibition may allow the elimi-
nation of CSCs.
Notch3, one of the four Notch receptors triggering the
Notch signaling pathway, has been reported as a candidate
oncogene overexpressed in more than 20% of ovarian serous
adenocarcinomas. In different tumor contexts, including
ovarian cancer, its deregulated expression was found to be
correlated with tumor recurrence, drug resistance, and a poor
prognostic outcome [7, 18–21].
In this review, we draw a picture on the current
knowledge about the role of Notch3 in ovarian CSC
behavior regulation, in order to suggest potential Notch3
inhibition-based cancer treatments aimed at improving
the prognosis of OC patients.
2. CSCs in Ovarian Cancer
In recent years, several models of CSC biology have been
proposed to explain how tumor heterogeneity develops and
contributes to the early stage of tumor formation, disease
progression, and drug resistance [22]. The CSC intratumoral
heterogeneity is a common feature described in several
tumors and OC represents one of the best examples [23, 24].
Indeed, tumor masses are composed of different cell types,
recognized upon their phenotype and function, and CSCs
represent a small subset of tumor cells, possessing
self-renewing properties. Furthermore, CSCs are also able
to generate nontumorigenic cell progeny, also called
non-CSC [25], which makes up most of the tumor cell
population and encompasses distinct genetic and epige-
netic characteristics [26]. More recently, it has been also
suggested a model by which CSCs could acquire the ability
of self-renewal through the dedifferentiation of progenitor
cells and the phenotype reversal of terminally differenti-
ated cells [27]. Moreover, it has been proposed that tumor
microenvironment can trigger specific signals that are able
to change the phenotype of both CSCs and differentiated
cells independently from genetic mechanisms (i.e., muta-
tions), thus making them interconvertible [28–30].
Altogether, these data support the general notion that the
acquisition of genetic and epigenetic alterations by CSCs and
the influence of the specific microenvironment determine the
ability of CSCs to evade the systemic effects of standard
chemotherapies, thus mediating drug resistance and cancer
recurrence [31–34]. Although CSC targeting would be an
interesting option to overcome drug resistance, it is still a
big challenge. Understanding and further dissecting the
molecular mechanisms that control CSCs as well as the
specific markers for appropriate CSC identification, isolation
and characterization can have important implications for
improving cancer therapies. In this regard, also other impor-
tant aspects in CSC biology, such as the tumor cell origin [35]
and the role of microenvironment [36], need to be further
studied and considered.
Mouse model-derived established OC cell lines and
patient-derived samples of OC were used for ovarian CSC
isolation by using a number of cell surface markers, including
CD133, CD44, CD24, CD117, ALDH1A1, and EpCAM
[34, 37]. However, it has been reported that several of
these are not uniformly useful in identifying CSCs because
they are not exclusively expressed by OC tissues [38]. An
exhaustive review of ovarian CSC marker expression and
function has been recently published [39]. The heterogene-
ity of the identified ovarian CSC putative markers could
be due to different factors, mainly related to the heteroge-
neity of the disease itself, to the existence of different pools
of ovarian CSCs and to their high genetic and phenotypic
plasticity [39]. Therefore, the use of combinatorial markers
and the need for more specific markers and revelation
techniques to detect ovarian CSCs are urgent.
In this regard, an increasing number of studies have
demonstrated the important role of the side population
(SP) cells in the identification of ovarian CSCs, as SP cells
are able to maintain a typical “CSC phenotype,” including
regenerative and self-renewing capacities, tumorigenicity,
and resistance to therapy [34, 40–43]. However, it has been
also demonstrated that SP cells derived from different OC
cell lines could express different markers, thus defining a
potentially heterogeneous CSC compartment [23]. There-
fore, further investigations are required to isolate SP cells
possessing CSC properties with respect to non-SP cells, in
order to evolve the knowledge of CSC-based therapies for
future OC treatment.
Several lines of evidence have demonstrated that CSCs
may confer growth advantage and metastatic properties to
chemoresistant ovarian tumors [34, 44, 45] through complex
mechanisms, which are not fully understood as yet. CSCs
may be related with several mechanisms including cell cycle
arrest, increased DNA protection, repair enzyme system,
and inherent epigenetic aberrations [46]. Furthermore, it
has been demonstrated that the decreased chemotherapy
responsiveness of CSCs could be also due to the activation
of several CSC-related prosurvival signaling pathways,
such as Wnt/β-catenin, IL6/JAK/STAT3, Hedgehog, NFκB,
PI3K/AKT, PDGFR, and Notch [46, 47], making them
possible key targets for eradicating CSC populations and
impairing metastatic behavior.
The OC therapy could be strongly supported by research
derived from CSC characterization, aimed at identifying
compounds that show significant potential for future person-
alized medicine based on the development of ovarian
CSC-specific therapeutic agents [48, 49].
3. Notch3 Signaling Overview
Notch signaling pathway includes receptors, ligands, positive
and negative modifiers as well as various transcription
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factors. In the vertebrates, four Notch receptors (Notch 1-4)
and two ligand families (delta-like 1, 3, 4 and Jagged 1, 2)
were identified. From a structural point of view, Notch
receptors are transmembrane proteins, consisting of an
extracellular portion which is rich in the epidermal growth
factor (EGF) repeats, a transmembrane domain and an
intracellular domain [49]. The canonical Notch signaling is
triggered when a Notch receptor interacts with a ligand
expressed by a neighboring cell. This binding leads to Notch
cleavage by a protease of the ADAM family, thus releasing its
extracellular portion and generating the substrate for subse-
quent cleavage of the Notch receptor intracellular domain
(NICD) by the γ-secretase complex. After this, the NICD
translocates to the nucleus where it interacts with a transcrip-
tion factor, called CSL (for CBF-1/RBP-Jκ, Suppressor of
Hairless and Lag-1), and a transcriptional coactivator of the
mastermind-like (MAML) family to form a transcriptional
activation complex [49].
3.1. Notch3 and Ovarian Cancer. The Notch signaling path-
way has been implicated in numerous human malignan-
cies [50]. In particular, Notch3 pathway dysregulation is
often associated with the pathogenesis and progression of
several tumors [51–54], including OC [55]. The amplifica-
tion of the chr19p13.12 region, encompassing the Notch3
locus, and the upregulation of Notch3 expression, both
at mRNA and protein levels, have been detected in a large
percentage of OC [56]. Notch3-overexpressing tumors
require Notch3 for proliferation and survival, thus suggest-
ing that the specific inactivation of Notch3 can represent a
potential therapeutic approach for OC patients. Indeed,
the selective downregulation of Notch3 by using either
Notch3-specific small interfering RNA (siRNA) or γ-secre-
tase inhibitors (GSIs) significantly reduced cell prolifera-
tion and induced apoptosis in Notch3-overexpressing cell
lines but not in cell lines that expressed a minimal amount
of Notch3 [56]. Park and colleagues further demonstrated
that Notch3 activation is strongly correlated with carbo-
platin resistance, as retrovirally driven NICD3 transduced
in OC cells was sufficient to increase cell survival upon
carboplatin treatment [7]. Interestingly, the presence of
nuclear NICD3 was observed more frequently in postche-
motherapy recurrent ovarian serous carcinomas than in
their primary counterparts, thus suggesting that the activa-
tion of Notch3 signaling may be advantageous for cancer
cell survival under the selection pressure of chemotherapy
[7]. In addition, NICD3 overexpression in OC cells
resulted in the upregulation of several stem cell markers,
such as Nanog, Oct4, Klf4, Rex1, and NAC1, as well as
of ABCB1 gene, which is a member of the superfamily
of ATP-binding cassette (ABC) transporters, known to be
involved in multidrug resistance through a mechanism of
drug efflux pumping [57]. In agreement with these data,
the CSC markers ALDH1A1 and CD44, which were found
highly expressed in non-small-cell lung cancer (NSCLC)
patients with chemoresistance, were positively correlated
with Notch3 expression [58]. Notably, Notch3 blockade
led to the prevention of the autophagy process commonly
related to chemoresistance of CSCs [58].
Furthermore, it has been also demonstrated that Notch3
inhibition abrogated the colony and tumor-forming ability of
ALDH-positive cells in lung cancer [59, 60]. Consistent with
these data, Ali and colleagues provided significant mechanis-
tic insights into how Notch3 was able to drive a stem-like
phenotype and tumorigenesis ability of KRAS lung adeno-
carcinoma (LDAC), the most prevalent form of lung cancer
characterized by poor therapeutic response and high relapse
rate [28].
3.2. Notch3 and Ovarian Cancer Stem Cells. It has been
recently demonstrated that Notch3 is overexpressed in
ALDH1+ ovarian cells [61], thus supporting again the link
between Notch3 and CSC function, as ADLH1 is reported
to be the most potent ovarian CSC marker [62] and high
expression of ALDH1 mRNA was associated with advanced
clinical stage and chemoresistance [63]. Interestingly, Kim
and colleagues showed for the first time the clinical signifi-
cance of Notch3 and ADHL1 coexpression observed in
human OC tissues, suggesting that their combined upregula-
tion represents an independent poor prognostic indicator in
OC [61].
The acquisition of a “stemness phenotype” through a
Notch3-dependent mechanism suggests a link between
Notch3 activation and drug resistance, and therefore tumor
recurrence, as stem cell-like properties are known to be
involved in chemoresistance development.
In keeping with these data, Kang and colleagues showed
that Notch inhibition in paclitaxel-resistant ovarian cancer
cells significantly results in reduced viability, migration, and
angiogenesis and increased apoptosis. Notably, both
pan-Notch inhibitors GSIs and Notch3 siRNA treatments
induce decreased spheroid formation, which represents the
self-renewal ability of CSCs, accompanied by a significant
downregulation of stem cell markers such as ALDH1,
CD24, CD44, CD133, SOX2, and c-kit (CD117) in resistant
cells, thus indicating that Notch3 blocking inhibits ovarian
CSC activation. Together, these data demonstrated that
Notch3-specific inhibition resensitizes paclitaxel-resistant
ovarian cancer cells to paclitaxel with an efficacy comparable
to GSIs [64].
The studies by McAuliffe and colleagues strongly
supported the specific role of Notch3 signaling pathway in
CSC maintenance and tumor resistance to platinum both
in vitro and in vivo [6]. By using animal models and human
tumor samples, the authors fully characterized the side pop-
ulation, previously isolated for their ability to efflux the
Hoechst 33342 fluorescent dye [65], demonstrating that SP
cells are enriched for ovarian CSCs, based on their transcrip-
tional profile, which showed upregulation of gene coding for
key stem cell surface markers, multidrug transporters,
self-renewal, DNA repair, angiogenesis, and differentiation.
Furthermore, CSCs overexpress high levels of genes associ-
ated with pivotal signaling pathways, including Notch,
TGF-β, IGF, EGF, FGF, and WNT/β-catenin [6]. OC SP
cells are more tumorigenic than non-SP (NSP) cells
in vivo and display an increased resistance to platinum
[6]. Interestingly, the authors demonstrated that standard
platinum therapy targets mostly NSP cells, whereas GSIs
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target Notch-dependent cells, including SP. They showed
that only the cisplatin/GSI combined treatments may be
effective in targeting both CSCs and the bulk of tumor
cells, thus being critical for tumor eradication, and finally
increasing platinum response and cell death by enhancing
the DNA damage response. Notably, the sensitivity to
GSIs was correlated with the presence of Notch3 gene
expression, thus further confirming the same results
obtained by using Notch3 siRNA knockdown [6]. Interest-
ingly, they also suggested including Notch inhibitors in the
first-line platinum treatment of OC to achieve the best
therapeutic results, as they observed that relapsed tumor
cells, including CSCs, were no longer completely depen-
dent on the Notch signaling pathway [6]. In keeping with
this, the usefulness of Notch3 as a prognostic biomarker
and a therapeutic target in patients with advanced stage
OC has been suggested, since the overexpression of
NICD3 observed in primary OC was also highly predictive
of a shorter progression-free interval [66].
All these studies support the notion that Notch3 activa-
tion may reprogram tumor cells to assume a stem-like profile
and contribute to platinum chemoresistance in OC, which is
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Figure 1: Diagramof theNotch3 signaling pathway in ovarianCSC. (a) InNotch3-overexpressing ovarianCSC,Notch signaling is triggered by
ligand binding to Notch3 receptor, which undergoes a two-step proteolytic cleavage by ADAM family proteases and γ-secretases, respectively.
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responsible for tumor recurrence. These findings may have
important therapeutic implications in the treatment of OC
patients (Figure 1).
4. Conclusion
One of the critical challenges in the treatment of patients
with OC is the development of chemoresistant recurrent dis-
ease, mainly due to the presence of a higher proportion of
CSCs with drug-resistance phenotype embedded within bulk
tumors. For this reason, there is considerable interest in the
development of new compounds that may be therapeutically
effective against this insidious subpopulation of tumor cells.
Several studies correlated Notch3 with CSC activation
and maintenance, thus suggesting that NICD3 expression
may represent a novel clinical parameter for the prediction
of patient survival and providing a rationale for future devel-
opment of Notch3-based therapy for OC.
Besides its central role in T-cell acute leukemia (T-ALL)
development, the activation of Notch signaling actually rep-
resents a possible target in several solid tumors, and for this
reason a number of novel Notch inhibitory strategies have
been undertaken [67].
Targeting the Notch pathway either with small mole-
cules, acting as γ-secretase inhibitors (GSIs), or large mole-
cules, such as monoclonal antibodies (mAbs) against Notch
receptors, is in clinical development [68]. Although GSI
treatment has progressed into the clinic, it fails to distinguish
individual Notch receptors and causes intestinal toxicity,
attributed to the dual inhibition of Notch1 and Notch2
[69]. Therefore, the specific inhibition of a single Notch
receptor or ligand might provide a less toxic alternative for
Notch inhibition.
Conventional platinum-based
chemotherapy
Ovarian cancer Self-renewal of
chemoresistant CSCs 
Tumor recurrence
Poor prognosis
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Ablation of CSC drug
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Figure 2: A proposed model for therapeutic approaches targeting ovarian CSC. (a) Conventional chemotherapy targets the cells that
constitute the bulk of the tumor, but CSCs frequently develop drug resistance and their subsequent enrichment generally leads to tumor
recurrence and poor prognosis. (b) Combined therapies involving inhibition of Notch signaling by using conventional drugs, such as GSI
as pan-Notch inhibitor, are able to sensitize CSCs to chemotherapy and ameliorate patients’ prognosis but are associated with intestinal
toxicity. (c) Combined therapies, targeting CSCs through the specific Notch3 inhibition, can potentially result in tumor regression and
reduced toxicity.
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Multiple studies have demonstrated that specific
Notch3 inhibition sensitizes tumor cells to chemotherapy
in drug-resistant OC, with an efficacy comparable to GSIs
[6, 64]. Furthermore, it has been recently demonstrated
that miR-136 overexpression, by directly targeting Notch3,
resensitized paclitaxel-resistant OC cells and reduced CSC
activities [70]. Actually, miRNA-targeting therapies are in
preclinical and clinical development for the treatment of
different diseases and cancers and targeting miRNAs
related to Notch would be a valuable therapeutic option
in OC treatment.
Together, all these findings strongly support the impor-
tance of new clinical trials aimed at evaluating more selective
and less toxic Notch3-based specific therapies in increasing
sensitivity to platinum treatment, finally improving the out-
comes of OC patients (Figure 2).
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